Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.3999 http://scihub22266oqcxt.onion/10.18632/oncotarget.3999 C4741843!4741843 !26369833     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26369833 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Oncotarget 2015 ; 6 (37 ): 39521-37 Nephropedia Template TP {{tp|p=26369833 |t=2015. Novel agents for advanced pancreatic cancer |pdf=|usr=}}{{26369833 }} gab.com Text Novel agents for advanced pancreatic cancer JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=26369833 #FOAvip Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-?, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer. Twit Text FOAVip Novel agents for advanced pancreatic cancer ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=26369833 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26369833 #FOAvip English Wikipedia <ref>{{Cite pmid|26369833 }}</ref> Novel agents for advanced pancreatic cancer #MMPMID26369833 Akinleye A ; Iragavarapu C ; Furqan M ; Cang S ; Liu D Oncotarget 2015[Nov]; 6 (37 ): 39521-37 PMID26369833 show ga Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-?, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer. |Antibodies, Monoclonal/*therapeutic use [MESH] |Antineoplastic Combined Chemotherapy Protocols/*therapeutic use [MESH] |Clinical Trials as Topic [MESH] |Humans [MESH] |Immunoconjugates/*therapeutic use [MESH] |Pancreatic Neoplasms/*drug therapy/metabolism [MESH] |Signal Transduction/*drug effects [MESH] |Small Molecule Libraries/*therapeutic use [MESH] |Survival Analysis [MESH]Novel agents for advanced pancreatic cancer (epmc).pdf DeepDyve Pubget Overpricing